Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsPatients with high-risk DCIS were enrolled in this 3×3 Phase I dose-escalation pilot study of two, four and eight mg intralesional injections of the PD-1 immune checkpoint inhibitor, pembrolizumab.
[npj Breast Cancer]
6445212 LM4A8VZM items 1 apa 0 default asc 1 162580 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-588ad43ecf4d75dbccddc3e5fff9ff11%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22LM4A8VZM%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Glencer%20et%20al.%22%2C%22parsedDate%22%3A%222021-05-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGlencer%2C%20A.%20C.%2C%20Wong%2C%20J.%20M.%2C%20Hylton%2C%20N.%20M.%2C%20Krings%2C%20G.%2C%20McCune%2C%20E.%2C%20Rothschild%2C%20H.%20T.%2C%20Loveday%2C%20T.%20A.%2C%20Alvarado%2C%20M.%20D.%2C%20Esserman%2C%20L.%20J.%2C%20%26amp%3B%20Campbell%2C%20M.%20J.%20%282021%29.%20Modulation%20of%20the%20immune%20microenvironment%20of%20high-risk%20ductal%20carcinoma%20in%20situ%20by%20intralesional%20pembrolizumab%20injection.%20%3Ci%3ENpj%20Breast%20Cancer%3C%5C%2Fi%3E%2C%20%3Ci%3E7%3C%5C%2Fi%3E%281%29%2C%201%26%23x2013%3B10.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41523-021-00267-z%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41523-021-00267-z%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DLM4A8VZM%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Modulation%20of%20the%20immune%20microenvironment%20of%20high-risk%20ductal%20carcinoma%20in%20situ%20by%20intralesional%20pembrolizumab%20injection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexa%20C.%22%2C%22lastName%22%3A%22Glencer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jasmine%20M.%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nola%20M.%22%2C%22lastName%22%3A%22Hylton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregor%22%2C%22lastName%22%3A%22Krings%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22McCune%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harriet%20T.%22%2C%22lastName%22%3A%22Rothschild%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tristan%20A.%22%2C%22lastName%22%3A%22Loveday%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20D.%22%2C%22lastName%22%3A%22Alvarado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20J.%22%2C%22lastName%22%3A%22Esserman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Campbell%22%7D%5D%2C%22abstractNote%22%3A%22Ductal%20carcinoma%20in%20situ%20%28DCIS%29%20is%20a%20risk%20factor%20for%20the%20subsequent%20development%20of%20invasive%20breast%20cancer.%20High-risk%20features%20include%20age%20%3C45%20years%2C%20size%20%3E5%5Cu2009cm%2C%20high-grade%2C%20palpable%20mass%2C%20hormone%20receptor%20negativity%2C%20and%20HER2%20positivity.%20We%20have%20previously%20shown%20that%20immune%20infiltrates%20are%20positively%20associated%20with%20these%20high-risk%20features%2C%20suggesting%20that%20manipulating%20the%20immune%20microenvironment%20in%20high-risk%20DCIS%20could%20potentially%20alter%20disease%20progression.%20Patients%20with%20high-risk%20DCIS%20were%20enrolled%20in%20this%203%5Cu2009%5Cu00d7%5Cu20093%20phase%201%20dose-escalation%20pilot%20study%20of%202%2C%204%2C%20and%208%5Cu2009mg%20intralesional%20injections%20of%20the%20PD-1%20immune%20checkpoint%20inhibitor%2C%20pembrolizumab.%20Study%20participants%20received%20two%20intralesional%20injections%2C%20three%20weeks%20apart%2C%20prior%20to%20surgery.%20Tissue%20from%20pre-treatment%20biopsies%20and%20post-treatment%20surgical%20resections%20was%20analyzed%20using%20multiplex%20immunofluorescence%20%28mIF%29%20staining%20for%20various%20immune%20cell%20populations.%20The%20intralesional%20injections%20were%20easily%20administered%20and%20well-tolerated.%20mIF%20analyses%20demonstrated%20significant%20increases%20in%20total%20T%20cell%20and%20CD8%2B%20T%20cell%20percentages%20in%20most%20patients%20after%20receiving%20pembrolizumab%2C%20even%20at%20the%202%5Cu2009mg%20dose.%20T%20cell%20expansion%20was%20confined%20primarily%20to%20the%20stroma%20rather%20than%20within%20DCIS-containing%20ducts.%20Neither%20cleaved%20caspase%203%20%28CC3%29%20staining%2C%20a%20marker%20for%20apoptosis%2C%20nor%20DCIS%20volume%20%28as%20measured%20by%20MRI%29%20changed%20significantly%20following%20treatment.%20Intralesional%20injection%20of%20pembrolizumab%20is%20safe%20and%20feasible%20in%20patients%20with%20DCIS.%20Nearly%20all%20patients%20experienced%20robust%20total%20and%20CD8%2B%20T%20cell%20responses.%20However%2C%20we%20did%20not%20observe%20evidence%20of%20cell%20death%20or%20tumor%20volume%20decrease%20by%20MRI%2C%20suggesting%20that%20additional%20strategies%20may%20be%20needed%20to%20elicit%20stronger%20anti-tumor%20immunity.%22%2C%22date%22%3A%222021-05-25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41523-021-00267-z%22%2C%22ISSN%22%3A%222374-4677%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41523-021-00267-z%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-05-25T16%3A51%3A15Z%22%7D%7D%5D%7D
Glencer, A. C., Wong, J. M., Hylton, N. M., Krings, G., McCune, E., Rothschild, H. T., Loveday, T. A., Alvarado, M. D., Esserman, L. J., & Campbell, M. J. (2021). Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection. Npj Breast Cancer, 7(1), 1–10. https://doi.org/10.1038/s41523-021-00267-z Cite
